- Home
- THFF vs EYPT Comparison
THFF vs EYPT Comparison
Compare THFF & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THFF | EYPT |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.4M | 1.5B |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | THFF | EYPT |
|---|---|---|
| Price | $60.70 | $12.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $62.00 | $31.80 |
| AVG Volume (30 Days) | 50.8K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | ★ 67.00 | N/A |
| EPS | ★ 6.68 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $17.86 | N/A |
| Revenue Next Year | $3.55 | $965.51 |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.05 | $3.91 |
| 52 Week High | $69.21 | $19.11 |
Technical Indicators
Market Signals| Indicator | THFF | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 37.11 | 35.42 |
| Support Level | $50.83 | $11.88 |
| Resistance Level | $63.04 | $14.24 |
| Average True Range (ATR) | 1.76 | 1.16 |
| MACD | -0.50 | -0.43 |
| Stochastic Oscillator | 15.41 | 0.17 |
Price Performance
Historical ComparisonAbout THFF First Financial Corporation Indiana
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.